JOHANNESBURG, SOUTH AFRICA — Nearly 55,000 South Africans have received the twice-yearly lenacapavir injection since public health facilities initiated the rollout in June 2026. According to data compiled on 8 September 2026, the long-acting injectable pre-exposure prophylaxis (LEN)—which provides six months of HIV protection per administration—is now active across roughly 360 government clinics across six provinces. Free State, Limpopo, and Northern Cape are not yet participating in the initial phase.
The initial administration requires two subcutaneous injections and four oral tablets—two taken on launch day and two taken the following day—followed by repeat injections every 24 to 28 weeks.
Priority Demographics and Provincial Distribution under South Africa Lenacapavir Rollout
The initial phase prioritizes key demographics at elevated risk, including adolescent girls and young women (aged 15–24), sex workers, transgender women, gay and bisexual men, and pregnant or breastfeeding women. Regional distribution highlights uneven provincial uptake led by Gauteng and KwaZulu-Natal.
Province / Priority Metric
Active Clinic Sites
Primary Target Groups
Gauteng Province
Over 120 Clinics
Young women, urban students, peer educators
KwaZulu-Natal (KZN)
~90 Clinics
Pregnant & breastfeeding women, youth
Western Cape
22 Clinics
Sex workers, mobile community clinic users
Non-Participating Regions
Free State, Limpopo, Northern Cape
Pending Phase 2 clinic expansion
Long-Term Epidemic Impact and Scaling Up Supply
Epidemiological modeling indicates that between 1 and 2 million people must receive the injection annually through 2043 to drastically reduce national HIV incidence—a target far surpassing present capacity.
To bridge this gap, supply availability under the South Africa lenacapavir rollout relies on upcoming generic manufacturing approvals. Expanding local supply remains vital to scaling clinic access beyond the current 10% coverage mark.
Why It Matters: South Africa’s execution curve establishes the foundational benchmark that other African nations will measure against as global supply chains for injectable lenacapavir broaden.
South Africa Lenacapavir Rollout: Over 3,600… CAPE TOWN, SOUTH AFRICA — The ongoing South Africa lenacapavir rollout has reached a major landmark, with more than 3,600 individuals initiating the twice-yearly injectable HIV prevention medication across Western Cape public clinics. According to…
Zoladex 3.6mg Implant (Goserelin): Uses,… Managing hormone-sensitive cancers and gynecological conditions requires consistent, targeted suppression of circulating sex hormones. This essential Zoladex 3.6mg implant guide details how this monthly goserelin injection works, clinic administration procedures, expected side effects, and critical…
Stopping HIV in its Tracks: The Role of PrEP and PEP HIV remains one of the most pressing public health challenges in Africa. According to UNAIDS, over 25 million people in Sub-Saharan Africa are living with HIV, and thousands of new infections occur every day. While…
South Africa HIV Prevention Jab Reaches 55000 People CAPE TOWN, SOUTH AFRICA — Nearly 55,000 South Africans have received lenacapavir, the twice-yearly injectable HIV prevention drug, since its national deployment commenced on 5 June 2026. The South Africa HIV prevention jab is currently…
